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Simple Summary: Germline pharmacogenomic variants impact the toxicity of many cancer treatment
drugs. Though testing for pharmacogenomic variants prior to initiating systemic cancer treatment
is not routine, the Clinical Pharmacogenetics Implementation Consortium recommends dosing
modifications for six cancer treatment drugs based on variant genotypes: irinotecan and UGT1A1;
5-fluorouracil and capecitabine and DPYD; 6-mercaptopurine and thioguanine and TPMT; and
tamoxifen and CYP2D6. The purpose of this study was to assess the frequency of cancer treatment-
relevant germline pharmacogenomic variants in patients with cancer using residual germline whole-
exome sequencing. We also evaluated the association of disease-relevant pharmacogenomic variants
with treatment-associated toxicities. Approximately one-quarter of cancer patients carried a disease-
relevant pharmacogenomic variant. Patients with toxicity-associated pharmacogenomic variant
genotypes were more likely to experience drug-related toxicity than their wild-type counterparts.
Universal pharmacogenomic screening is feasible using whole-exome sequencing originally obtained
for quality control purposes and may be an effective germline pharmacogenomic screening strategy
for patients who are candidates for irinotecan, 5-fluorouracil, capecitabine, or 6-mercaptopurine.
Abstract: The purpose of this study was to determine the frequency of clinically actionable treatment-
relevant germline pharmacogenomic variants in patients with cancer and assess the real-world
clinical utility of universal screening using whole-exome sequencing in this population. Cancer
patients underwent research-grade germline whole-exome sequencing as a component of sequencing
for somatic variants. Analysis in a clinical bioinformatics pipeline identified clinically actionable
pharmacogenomic variants. Clinical Pharmacogenetics Implementation Consortium guidelines
defined clinical actionability. We assessed clinical utility by reviewing electronic health records to
determine the frequency of patients receiving pharmacogenomically actionable anti-cancer agents
and associated outcomes. This observational study evaluated 291 patients with cancer. More than
90% carried any clinically relevant pharmacogenetic variant. At least one disease-relevant variant
impacting anti-cancer agents was identified in 26.5% (77/291). Nine patients with toxicity-associated
Cancers 2021, 13, 4524. https://doi.org/10.3390/cancers13184524 https://www.mdpi.com/journal/cancers
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pharmacogenomic variants were treated with a relevant medication: seven UGT1A1 intermediate
metabolizers were treated with irinotecan, one intermediate DPYD metabolizer was treated with
5-fluorouracil, and one TPMT poor metabolizer was treated with mercaptopurine. These individuals
were more likely to experience treatment-associated toxicities than their wild-type counterparts (p =
0.0567). One UGT1A1 heterozygote died after a single dose of irinotecan due to irinotecan-related
adverse effects. Identifying germline pharmacogenomic variants was feasible using whole-exome
sequencing. Actionable pharmacogenetic variants are common and relevant to patients undergoing
cancer treatment. Universal pharmacogenomic screening can be performed using whole-exome
sequencing data originally obtained for quality control purposes and could be considered for patients
who are candidates for irinotecan, 5-fluorouracil, capecitabine, and mercaptopurine.
Keywords: pharmacogenomics; cancer; real word; irinotecan; 5-fluorouracil; mercaptopurine
1. Introduction
Germline pharmacogenomic variants influence the metabolism of environmental tox-
ins and affect patient response to medications. In 2009, the United States (US) Food and
Drug Administration (FDA) added drug labeling for pharmacogenomic considerations [1],
and the list now includes over 450 drugs [2]. The Clinical Pharmacogenetics Implementa-
tion Consortium (CPIC) helps clinicians and pharmacists navigate this complex genetic
information and highlights the level of evidence supporting each pharmacogenomic vari-
ant’s importance [3,4]. CPIC provides evidence-based variant-specific prescribing guidance;
currently, there are twenty pharmacogenes classified in level A status [3,4].
Oncology medications comprise 41.4% (189/457) of all medicines listed by the US FDA
with pharmacogenomic considerations and 57.1% (108/189) of these medications are listed
for reasons due to risk of adverse events, contraindications, boxed and other warnings, and
medication precautions [2]. In addition, our institution previously reported that 65% of
advanced cancer patients were taking a pharmacogenomically actionable medication [5].
Despite data suggesting benefit, pharmacogenomic screening is not routinely per-
formed in clinical practice [6] due to logistical barriers, cost, and lack of clinical utility [7].
A possible solution to overcome logistical obstacles is the implementation of universal ac-
tionable pharmacogenomic variant screening [7]. Additionally, somatic mutation testing to
guide treatment is now routine for many patients with cancer and paired somatic/germline
sequencing is often performed to reliably distinguish between germline and somatic mu-
tations. While initially used as a quality control measure to avoid reporting incidental
germline findings [8], this germline testing may provide an opportunity to also assess
pharmacogenomic variants using existing sequencing data [9,10]. Hertz and colleagues
(2018) reported that the Michigan Oncology Sequencing program could determine germline
TPMT, DPYD, and CYP2C19 genotype at no additional cost [11]. The purpose of this study
is to determine the frequency of clinically actionable germline variants in patients with
cancer and assess the real-world clinical utility of universal screening using germline
whole-exome sequencing (WES) originally obtained for quality control purposes.
2. Results
2.1. Study Population and Pharmacogenomic Landscape
Between October 2018 and January 2021, we prospectively enrolled 291 cancer patients,
regardless of cancer type. Table 1 summarizes the demographic characteristics. The median
age was 61 (inter-quartile range 52–68), and most individuals were non-Hispanic and White
(277/291, 95.2%), with fourteen (14/291, 4.8%) non-Hispanic and Black individuals also
participating. Approximately equal numbers of men and women participated.
Pharmacogenomic variants were common and are reported in Table 2. Overall, 90.4%
(263/291) of cancer patients carried any pharmacogenomic variant. No CFTR, CYP2C19,
CACNA1S, or HLA-B variants were detected; however, testing was limited for CFTR
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(*c.1652G>A only), CYP2C19 (*7 only), and HLA-B (*57:01, *15:02, and *58:01 only). A full
listing of variants included in analysis is available in Appendix A. Although population
allele frequencies vary by race and ethnicity, allele frequencies in our cohort were similar
to expected American or European population frequencies [3] except for a higher than
expected frequency of RYR1 variants, which was present in two patients and demonstrated
an allele frequency of 0.0034.
Table 1. Patient demographics and disease characteristics.
Characteristic Patients (n) %
Total 291
Age (median) 61 IQR: 52–68
Race
Non-Hispanic Black 14 4.8%













Kidney and bladder 14 4.8%
Lung 14 4.8%
Small bowel 2 12 4.1%
Skin 12 4.1%
Breast 7 2.4%






N/A 4 47 16.2%
Abbreviations: IQR: inter-quartile range; N/A: not available or not applicable. 1 One patient identified as
a transgender and was assigned male at birth. 2 Small bowel histologies included adenocarcinoma, carci-
noid/neuroendocrine tumor, and sarcoma. 3 Other primary sites included anus, peripheral nervous system,
prostate, soft tissue, and thyroid gland. 4 N/A includes cancers that are not staged or whose stage was unavailable.
Table 2. Pharmacogenomic variants and patient frequencies. The number of patients and percentage refers to heterozygotes
unless otherwise specified.








0.3093 0.3165Homozygote 23 (7.9%)
Heterozygote 134 (46.0%)
Total UGT1A1 157 (54.0%) 0.3093 0.3165
DPYD
*c.2846A>T 1 (0.3%) 0.0017 0.0037
*2A 4 (1.4%) 0.0069 0.0079
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Table 2. Cont.





*HapB3 7 (2.4%) 0.0120 0.0237
*c.557A>G 1 (0.3%) 0.0017 0.0001
*7 1 (0.3%) 0.0017 0.0002
Total DPYD 14 (4.8%) 0.0240 0.0353
TPMT
*3A
0.0601 0.0343Homozygote 2 (0.7%)
Heterozygote 31 (10.7%)
*3B 1 (0.3%) 0.0017 0.0027
*3C
0.0123 0.0047Homozygote 1 (0.3%)
Heterozygote 3 (1.0%)
*2 2 (0.7%) 0.0034 0.0021
Total TPMT 40 (14.0%) 0.0775 0.0438
CYP2D6
*6 5 (1.7%) 0.0086 0.0025
CYP2C9
*3 37 (12.7%) 0.0636 0.0301
*11 2 (0.7%) 0.0034 0.0028
Total CYP2C9 39 (13.4%) 0.0670 0.0329
CYP3A5
*6 3 (1.0%) 0.0052 0.0015
*7 2 (0.7%) 0.0034 0.0000
Total CYP3A5 5 (1.7%) 0.0086 0.0015
G6PD
A-202A_376G-III 1 (0.3%) 0.0017 0.0000–0.0340 2
CYP4F2
*3
0.2629 0.4108Homozygote 21 (7.2%)
Heterozygote 111 (38.1%)
Total CYP4F2 132 (45.0%)
SLCO1B1
*15 or *17 3
0.1186 0.1214 (*15); 0.0519 (*17)Homozygote 5 (1.7%)
Heterozygote 59 (20.3%)
*5
0.0241 0.0224Homozygote 2 (0.7%)
Heterozygote 10 (3.4%)
Total SLCO1B1 12 (4.1%) 0.1427 0.1957
VKORC1
*1173C>T
0.1409 0.4643Homozygote 11 (3.8%)
Heterozygote 60 (20.6%)
Total VKORC1 71 (24.4%)
RYR1
c.7042_7044delGAG 1 (0.3%) 0.0017 0.0000 4
c.14818G>A 1 (0.3%) 0.0017 0.0000 5
Total RYR1 2 (0.6%) 0.0034 0.0000 4,5
1 Expected American population variant allele frequencies were obtained from CPIC database [3] unless otherwise specified. When
expected American population variant frequency was not available, expected European population frequencies were reported. 2 Caucasian
prevalence of this G6PD variant is 0.0000; however, prevalence of any G6PD variant in the Americas is 0.0340. 3 Testing bait was unable
to differentiate SLCO1B1 *15 and *17 variants, so these frequencies were combined. 4 Population allele frequency for this variant was
obtained from the Genome Aggregation Database (gnomAD) [12]. 5 Population allele frequency for this variant was obtained from the
Exome Aggregation Consortium (ExAC) database [13].
Cancers 2021, 13, 4524 5 of 16
2.2. Clinical Impact
Many (189/291, 64.9%) oncology patients harbored pharmacogenomic variants in
genes that metabolize cancer therapeutic agents. Approximately one-quarter (26.5%,
77/291) carried at least one pharmacogenomic variant for at least one therapeutic option
indicated in their disease type. Table 3 summarizes the association between pharmacogenes,
their associated anti-cancer agents, National Comprehensive Cancer Network (NCCN)
guideline-recommended anti-cancer drugs, and the number of patients at risk. Although
most patients received systemic cancer treatments at our institution, several patients were
treated elsewhere. Follow-up data were not available for six colorectal, one pancreatic, and
one hepatobiliary cancer patient.
Consistent with the expected American/European population frequency, UGT1A1
variants were common (157/291, 54%). UGT1A1 genotype status impacts irinotecan
metabolism, often indicated for front-line treatment of gastrointestinal malignancies [14,15].
Over half (45/86, 52.3%) of the patients who could potentially receive irinotecan as a
component of an NCCN “preferred” regimen harbored a UGT1A1 variant. The fluo-
ropyrimidines capecitabine and fluorouracil are commonly included in cancer treatment
regimens [16], and several patients (14/291, 4.8%) carried a DPYD variant, which af-
fects the metabolism of these drugs. Similarly, TPMT is involved in the metabolism
of 6-mercaptopurine (6-MP) [17], which is often administered in acute lymphoblastic
leukemia (ALL) [18]; however, few ALL patients were enrolled in our study, and only one
received 6-MP.
Table 3. Pharmacogenes and their clinical relevance to cancer patients. Clinical Pharmacogenetics Implementation
Consortium (CPIC) level A pharmacogenes are listed with their associated anti-cancer drugs and associated malignancies
as per National Comprehensive Cancer Network (NCCN) guidelines. Patients at potential risk indicates patients with any
disease-relevant pharmacogenomic variants for each specified malignancy regardless of treatment received. Numerator
indicates patients with variant alleles and denominator includes all patients with specified malignancy. In other words, of
the 55 patients with colon/rectal cancer, 33 had UGT1A1 variants. Patients at actual risk indicates patients with variant
alleles for each associated malignancy who were treated with associated anti-cancer drugs at our institution. Numerator
indicates patients treated with specified drug and denominator includes all patients with specified malignancy with
associated variant allele. In other words, of the 55 patients with colon/rectal cancer, 27 patients had a UGT1A1 variant and
were treated at our institution; five of those patients received irinotecan.
Pharmacogene Anti-CancerDrug Malignancy
Patients at Potential
Risk (a 2/A 3)




Colon/rectal P 33/55 5/27 1
Pancreas P 7/16 2/6 1
Gastric/gastroesophageal P 4/15 0/4
Cervix O 1/1 0/1
Ovary O 16/25 0/16
Hepatobiliary O 5/7 0/4 1
Carcinoid/neuroendocrine O 6/10 0/6
Small bowel adenocarcinoma O 0/2 N/A 6
DPYD Capecitabine
Colon/rectal P 3/55 0/2 1
Pancreas P 1/16 0/1
Breast P 0/7 N/A
Ovary O 2/25 0/2
Cervix O 0/1 N/A
Anus O 0/1 N/A
Bladder O 0/3 N/A
DPYD Fluorouracil
Colon/rectal P 3/55 0/2 1
Pancreas P 1/16 1/1
Gastric/gastroesophageal P 1/15 1/1
Head and neck P 0/36 N/A




Risk (a 2/A 3)
Patients at Actual Risk
(b 4/B 5)
Toxicity-Associated Pharmacogenes
Anus O 0/1 N/A
Vulva O 0/1 N/A
Basal cell skin O 0/1 N/A
Squamous cell skin O 0/4 N/A
Bladder O 0/3 N/A
Thyroid O 0/4 N/A
Small bowel adenocarcinoma O 0/2 N/A
TPMT Mercaptopurine Acute lymphoblastic leukemia P 1/3 1/1
Efficacy-Associated Pharmacogenes
CYP2D6 Tamoxifen
Breast P 1/7 1/1
Ovary P 1/25 0/1
Uterus P 0/22 N/A
Abbreviations: N/A: not available. P Drug is a component of an NCCN “preferred regimen” for specified malignancy. O Drug is a
component of an NCCN “other regimen” and/or “regimen useful in certain instances” for specified malignancy. 1 Chemotherapy regimen
was unknown for several patients who received treatment at outside institutions. 2 Number of patients with any variant allele. 3 Number
of patients with this disease type. 4 Number of patients treated with drug; individuals treated outside of our institution are excluded. 5
Number of patients with any variant allele specific to drug; individuals treated outside of our institution are excluded. 6 If no patients with
variant alleles were treated at our institution, ‘N/A’ is indicated.
2.2.1. Adverse Effects
Figure 1 illustrates the association between treatment-relevant genotype and treatment
tolerance for patients prescribed CPIC level A drugs as a component of their cancer therapy.
Treatment and tolerance details for each patient are available in Appendix B. Associated
dosing of each treatment regimen is available in Appendix C. Of the six normal irinote-
can metabolizers (UGT1A1 *1/*1), only one (1/6, 16.7%) experienced irinotecan-related
diarrhea requiring a dose reduction. Five of seven (71.4%) UGT1A1 *28 heterozygotes
(irinotecan intermediate metabolizers) experienced any irinotecan-related toxicity. Toxici-
ties resulted in dose reductions (2/7, 14.3%), delays (1/7, 14.3%), and discontinuation (1/7,
14.3%); one patient received one cycle of irinotecan and presented with severe diarrhea,
ultimately resulting in renal failure and death after a protracted hospital stay (1/7 14.3%).
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olizers. FDA labeling does not require pharmacogenomic testing before initiating any 
CPIC level A cancer drugs [19]; however, our results suggest an increased risk of toxicity, 
including death, requiring clinical intervention for patients with treatment-relevant phar-
macogenomic variants.  
Though variant-associated toxicity is established for TPMT [17], UGT1A1 [15], and 
DPYD [16] intermediate and poor metabolizers, testing is not routinely performed and 
clinical management guidelines for dosing are inconsistent. This is likely related to logis-
tical barriers, lack of clinical utility, and cost associated with routine pharmacogenomic 
screening [7,11]. This research demonstrates germline WES data originally obtained for 
quality control purposes may be used to report pharmacogenomic variants. Germline se-
quencing data are increasingly available because of targeted treatment options and so-
matic mutation testing [10,11] and may represent a cost-effective strategy for both over-
coming barriers to pharmacogenetic testing and integrating germline and somatic se-
quencing to expand precision cancer care. 
Our results also demonstrate that pharmacogenomic variants are common; more 
than 90% of cancer patients carried at least one clinically actionable pharmacogenetic var-
Figure 1. Patient tolerance to genomically-relevant anti-cancer agents. Toxicities resulting in dosing modifications, cycle
delays, or discontinuation are reported. 6-mercaptopurine toxicity included cytopenia; irinotecan toxicities included
cytopenia and diarrhea; fluoropyrimidine toxicities included cytopenia, diarrhea, hepatotoxicity, mucositis/stomatitis, and
cardiotoxicity. Disease response is reported for the one patient who received tamoxifen as CYP2D6 is an efficacy-related
phar acogene. bbreviations: CPIC: Clinical Phar acogenetics I ple entation Consortiu ; t: ild type.
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Similarly, the only DPYD intermediate metabolizer (*c.557A>G heterozygote) treated
with a fluorouracil-containing regimen at our institution required treatment discontinu-
ation after one cycle due to poor tolerance. Fluorouracil-related treatment toxicity was
experienced by 40% (12/30) of normal DPYD metabolizers. Finally, the only patient in
our cohort treated with 6-MP was not clinically tested prior to treatment and experienced
profound cytopenia after the first dose. Genomic testing later revealed this patient was a
poor TPMT metabolizer (TPMT *3B/*3C).
Though our statistical power is limited by a small sample size, patients with toxicity-
associated variant alleles were more likely to experience toxicities resulting in treatment
delays, dose reductions, or discontinuation of chemotherapy than those who did not carry
a variant metabolism gene (7/9, 77.8% vs. 13/36, 36.1%; p = 0.0567) when treated with a
pharmacogenomically-relevant drug.
2.2.2. Efficacy
In our cohort, one intermediate tamoxifen metabolizer (CYP2D6*1/*6) was treated
with tamoxifen. This patient experienced progressive disease with standard (20 mg daily)
tamoxifen dosing and required alternative anti-estrogen treatment with an aromatase
inhibitor and surgical castration. No additional patients were treated with tamoxifen for
comparison purposes.
3. Discussion
Our results suggest the feasibility and potential benefit of pharmacogenomic vari-
ant genotyping for cancer patients using WES obtained for quality control purposes in
a real-world setting. Though our numbers are small, patients with treatment-relevant
pharmacogenomic variants experienced increased rates of toxicity compared to normal
metabolizers. FDA labeling does not require pharmacogenomic testing before initiating
any CPIC level A cancer drugs [19]; however, our results suggest an increased risk of toxi-
city, including death, requiring clinical intervention for patients with treatment-relevant
pharmacogenomic variants.
Though variant-associated toxicity is established for TPMT [17], UGT1A1 [15], and
DPYD [16] intermediate and poor metabolizers, testing is not routinely performed and
clinical management guidelines for dosing are inconsistent. This is likely related to logis-
tical barriers, lack of clinical utility, and cost associated with routine pharmacogenomic
screening [7,11]. This research demonstrates germline WES data originally obtained for
quality control purposes may be used to report pharmacogenomic variants. Germline se-
quencing data are increasingly available because of targeted treatment options and somatic
mutation testing [10,11] and may represent a cost-effective strategy for both overcoming
barriers to pharmacogenetic testing and integrating germline and somatic sequencing to
expand precision cancer care.
Our results also demonstrate that pharmacogenomic variants are common; more than
90% of cancer patients carried at least one clinically actionable pharmacogenetic variant.
Furthermore, our findings suggest potential clinical utility. In this unselected population,
15.8% (46/291) of individuals received a genotype-relevant anti-cancer drug and ten of
these individuals carried a variant pharmacogene. Importantly, while our numbers are
small, patients with treatment-relevant pharmacogenomic variants experienced increased
rates of toxicity requiring clinical intervention and death compared to normal metabolizers.
US FDA labeling does not require pharmacogenomic testing before initiating any CPIC
level A cancer medications [19]. Regarding practice guidelines, ALL is the only disease
in which the NCCN recommends, but does not require, testing for the presence of TPMT
variants before 6-MP initiation [18]. The NCCN colon cancer guidelines advise caution
and suggest alternative dosing strategies for UGT1A1 poor metabolizers (UGT1A*28
homozygous variants) scheduled to receive irinotecan; however, no testing guidelines
have been established [19,20]. Conversely, these same guidelines note DPYD variants are
inconsistently associated with fluoropyrimidine toxicity and do not currently recommend
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pre-treatment testing [20]. Despite the role of irinotecan, fluorouracil, and capecitabine
in preferred NCCN treatment regimens for pancreatic [21] and gastroesophageal [22,23]
cancers, these pharmacogenomic variants are not discussed in the guidelines.
The oncology community has hesitated to initiate lower fluoropyrimidine doses for
patients with DPYD variants and lower irinotecan doses for UGT1A1 intermediate metab-
olizers because not all poor and intermediate metabolizers experience toxicity [15,16,24]
and treating with a lower dose may decrease the drug’s therapeutic efficacy [24]. In fact,
recent research demonstrated genotype-directed irinotecan dosing resulted in improved
pathologic complete responses and decreased irinotecan-related toxicity for UGT1A1 in-
termediate metabolizers (*1/*28) undergoing neoadjuvant chemoradiation for locally ad-
vanced rectal cancer [25]. Similarly, DPYD genotype-directed fluoropyrimidine dosing
demonstrated improved patient safety outcomes [26] without compromising efficacy in a
diverse group of patients treated with capecitabine or fluorouracil containing regimens [27].
Avoiding treatment-related toxicity is critical; patients who experience treatment-
related adverse events are more likely to discontinue treatment altogether [28], experience
dose reductions and delays, and ultimately experience worse survival outcomes [29,30].
Additionally, preemptive pharmacogenomic screening for DPYD variants is a cost-effective
approach for patients scheduled to receive fluoropyrimidine-based chemotherapy [31,32];
however, data remain mixed for assessing for TPMT variants in patients scheduled to re-
ceive 6-MP [33,34] and UGT1A1 variants in patients scheduled to receive irinotecan [35–38].
Therefore, we suggest an individualized genotype-directed dosing strategy for patients
scheduled to receive a pharmacogenomically-relevant anti-cancer medication.
Strengths of this study include a prospective population-level approach, novel use
of quality control germline data for identifying pharmacogenes, and assessment of the
real-world impact of pharmacogenes in patients with cancer. In addition, variant calling
was performed in a Clinical Laboratory Improvement Amendments setting with annotation
by a pathologist.
A potential limitation is the use of research-grade sequencing, which typically has
lower coverage than clinical sequencing; however, allele frequencies were consistent with
expected population allele frequencies suggesting this limitation is of minimal practical
consequence. As a single institutional study treating a largely rural and predominantly
non-Hispanic White population, generalizability may be limited. Furthermore, pharma-
cogenomic allele frequencies vary by race and ethnicity and our screening strategy has
not been tested in a diverse population. We also did not collect blood samples, precluding
an analysis of drug exposure, metabolizer status, and toxicity. Though patients were
prospectively enrolled in this study, clinical outcome data were collected retrospectively,
limiting clinical actionability. Finally, as our institution is a tertiary care center, many
patients enrolled in this study underwent surgical treatment at our institution but received
chemotherapy elsewhere, limiting sample size and follow-up data.
4. Materials and Methods
4.1. Study Design and Data Sources
This observational cohort study compared research-grade germline WES results to
clinical treatment data and patient outcomes. Patients treated at the University of Kentucky
Markey Cancer Center enrolled in the Total Cancer Care (TCC)® protocol.
TCC is a multi-institutional prospective cohort study and comprises data collected
from eighteen member institutions of the Oncology Research Information Exchange Net-
work (ORIEN). This cancer precision medicine initiative was first developed by the Moffitt
Cancer Center in Tampa, Florida, USA [39,40]. To date, over 315,000 participants have
enrolled, undergone germline and tumor somatic sequencing, and agreed to lifetime
follow-up [41].
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Demographic and clinical data were obtained from the Kentucky Cancer Registry
(KCR). Kentucky state statute (KRS 214.556) requires all cases of cancer diagnosed and/or
treated in Kentucky to be reported to this registry. This population-based cancer registry
reports demographic and clinical information, including the genetic data generated as a
component of the TCC protocol.
The Markey Cancer Center Cancer Research Informatics Shared Resource Facility (CRI
SRF) served as the honest broker and distributed data stored in the KCR. A contractual
agreement was previously established through M2GEN (Hudson, FL, USA) to permit data
sharing between ORIEN/TCC and KCR. All data were fully anonymized prior to analysis.
The final dataset for this study comprised the linked demographic, clinical, and genomic
data from KCR and ORIEN/TCC.
4.2. Study Population
Between October 2018 and January 2021, patients presenting to Markey Cancer Center
for cancer treatment were invited to enroll in TCC. Treating physicians informed eligible
patients about this study, and subjects were recruited during routine clinic visits. Eligibility
criteria for TCC required patients to be at least 18 years of age and have a diagnosis
of cancer. To be included in this analysis, each patient must have had germline WES
results available. All subjects provided written informed consent prior to study enrollment.
This study was conducted according to the guidelines of the Declaration of Helsinki, in
accordance with the US Common Rule and was approved by the Institutional Review Board
(IRB protocol code #44224, initial date of approval 28 June 2017 and modified to permit
return of research results to enrolling physicians on 12 October 2018) at the University of
Kentucky. Demographic variables included gender, race, and age at diagnosis. Clinical
variables included primary cancer site, histology, and American Joint Committee on Cancer
stage at diagnosis. Additional data elements, including treatment regimens, duration of
therapy, and adverse effects, were retrospectively abstracted from the electronic health
record under a separate IRB approval (IRB protocol code #51483, initial date of approval
3 June 2019). Data were collected and managed using Research Electronic Data Capture
(REDCap) hosted at the University of Kentucky [42,43].
4.3. Sequencing Methods
Buccal swabs were used to obtain samples for germline testing. Germline WES was
performed as a quality control measure as a component of the ORIEN/TCC protocol.
Preparation of M2GEN WES libraries involved hybrid capture using an enhanced Inte-
grated DNA Technology (Coralville, IA, USA) WES kit (38.7 megabases) with additional
custom-designed probes for double coverage of 440 cancer genes. Library hybridization is
performed at either single or 8-plex and sequenced on an Illumina (San Diego, CA, USA)
NovaSeq 6000 instrument generating 100 base pair paired reads. WES is performed on
tumor/normal matched samples with the normal covered at 100X and the tumor cov-
ered at 300X (additional 440 cancer genes covered at 600X) depth. We performed both
tumor/normal concordance and gender identity quality control checks. The minimum
threshold for hybrid selection was >80% of bases with >20X fold coverage; M2GEN WES
libraries typically met or exceeded 90% of bases with >50X fold coverage for tumor and
90% of bases with >30X fold coverage for normal samples.
4.4. Pharmacogenomic Variant Interpretation and Reporting of Results
An in-house bioinformatics pipeline was developed for analyzing and annotating
germline variants in fifteen of the twenty genes with CPIC level A drug recommendations.
NUDT15 and HLA-A variants were not included because probe coverage was suboptimal.
IFNL3 and IFNL4 variants were not included because of the uncommon clinical usage of
peginterferon alfa-2a and 2b. Haplotypes for each pharmacogene included in the testing
process are reported in Appendix A.
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Briefly, FASTQ files generated from an Illumina sequencer were aligned to the ref-
erence sequence of human genome (GRCh37) using Burrows–Wheeler Aligner (BWA
0.7.8) [44]. Aligned reads were converted to Binary Alignment Map format using Sequence
Alignment/Map tools software (V1.8) [45]. Variant calling was carried out using Genome
Analysis Toolkit (V4.0.12.0) [46] and VarScan (v2.3.9) [47]. Variants were annotated using
Ensembl Variant Effect Predictor (VEP_89) [48] and public databases, including ClinVar [49],
1000 Genomes [50], and the Genome Aggregation Database (gnomAD) [12].
Results of pharmacogenomic testing, including pharmacogene, variant allele, and
zygosity were reported to the Markey Cancer Center precision medicine team. This team
reviewed results and reported findings in a letter to the enrolling oncologist, which was
uploaded into the electronic medical record.
4.5. Assessment of Potential and Actual Risk for Pharmacogenomic Adverse Outcomes
CPIC defines level A evidence for drug–gene pairs where the preponderance of the
evidence is moderate or strong in favor of making drug prescribing changes based on a phar-
macogenomic marker [3]. In this study, we defined anti-cancer agents as medications in-
tended to treat cancer. Based on these criteria, there are currently six anti-cancer agents with
a CPIC level A recommendation: irinotecan and UGT1A1; 5-fluorouracil and capecitabine
and DPYD; 6-MP and thioguanine and TPMT; and tamoxifen and CYP2D6. To deter-
mine the number of patients potentially at risk for anti-cancer agent and pharmacogene-
associated adverse effects, we first reviewed NCCN guidelines for individual tumor types
included in our population for “preferred” and “other” regimens (Appendix D) that in-
cluded CPIC level A anti-cancer agents. Drugs included in “regimens useful in certain
instances” for specified malignancy were included in NCCN “other” regimens. Patients
with disease types with a “preferred” or “other” regimen specified in NCCN guidelines [51]
were considered potentially impacted by a pharmacogenomic variant.
The actual impact of pharmacogenomic variants on cancer treatment was deter-
mined by assessing dosing changes, discontinuation, hospitalization, or treatment-related
death resulting from known adverse effects associated with variant genotypes. These
included cytopenia and diarrhea for irinotecan; cytopenia, diarrhea, hepatotoxicity, mu-
cositis/stomatitis, and cardiotoxicity for fluoropyrimidines; and cytopenia for 6-MP. Specif-
ically, allergic reactions, fatigue, or patient requests resulting in drug discontinuation or
dose reductions were not considered dose- or genotype-related. Patients were evaluated
for toxicity by each CPIC level A drug and by individual genotype and, as a result, may
have been included in more than one toxicity analysis.
4.6. Statistical Analysis
We performed a descriptive analysis of clinical variable and genotype frequencies.
Expected monoallelic population pharmacogene frequencies were obtained from CPIC [3]
when available. When unavailable, the population expected frequencies were obtained
from the Exome Aggregation Consortium (ExAC) database [13] or gnomAD [12]. Expected
American population frequencies were prioritized, followed by expected European popu-
lation frequencies as the Kentucky population is 84% non-Hispanic White [52] and allele
frequencies vary by race and ethnicity. Fisher’s exact test was used to compare genotype
and frequency of treatment-related toxicity.
5. Conclusions
Pharmacogenomically actionable variants are common in patients with cancer and
were identified using a whole-exome sequencing approach. Individuals receiving relevant
anti-cancer drugs experienced more toxicities than wild-type individuals. Therefore, uni-
versal pharmacogenomic screening using this approach could be considered for patients
who are candidates for irinotecan, 5-fluorouracil, capecitabine, and 6-MP.
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Appendix A
Table A1. Genes and Variants Detectable from Whole-Exome Sequencing.
Gene Detectable Variants
CACNA1S All pathogenic/likely pathogenic variants a
CFTR *c.1652G>A
CYP2C19 *3, *5, *7, *10
CYP2C9 *3, *5, *6
CYP2D6 *6, *8, *14
CYP3A5 *2, *4, *6, *7, *8
CYP4F2 *3
DPYD *2A, *HapB3, *3, *7, *8, *10, *12, *13, *c.557A>G, *c.2846A>T
G6PD Class I deficiency
G6PD Class II deficiency
G6PD Class III deficiency
HLA-B *57:01, *15:02, *58:01 b
RYR1 All pathogenic/likely pathogenic variants a
SLCO1B1 *5, *15/*17 c
TPMT *2, *3A, *3B, *3C, *4, *11, *14, *15, *23, *29, *41
UGT1A1 *6, *27, *28, *36, *37
VKORC1 *1173C>T (in linkage with c.-1639G>A)
a CACNA1S and RYR1 were assessed as standard genes; all pathogenic and likely pathogenic variants were
reported. b These HLA-B variants were determined by the process of elimination. For example, if there are five
mismatched amino acids in the sequence to a specific genotype, then that genotype was excluded. c The depth of
sequencing reads were not enough to differentiate *15 and *17, so these variants were reported together.
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Appendix B
Table A2. Patient tolerance to genomically-relevant preferred anti-cancer agents by disease type. Toxicities resulting in dosing
modifications, cycle delays, or discontinuation are reported. Dosing for each regimen is available in Appendix C. Only patients
treated at our institution, for whom systemic treatment details were available, are reported. Irinotecan toxicities included cytopenia
and diarrhea; fluoropyrimidine toxicities included cytopenia, diarrhea, hepatotoxicity, mucositis/stomatitis, and cardiotoxicity;




Site Stage Regimen Cycles Notes
UGT1A1: Irinotecan Intermediate Metabolizers
*1/*28 Colon IIA FOLFIRI + bevacizumab 14 No documented toxicity
*1/*28 Colon IIB FOLFIRI 3 Toxicity-unrelated discontinuation
*1/*28 Colon IVA FOLFIRI + panitumumab 38 Toxicity-related cycle delay
*1/*28 Rectum IVA FOLFIRI 4 Toxicity-related dose reduction
*1/*28 Pancreas IB FOLFIRINOX 15 Toxicity-related dose reduction
*1/*28 Pancreas III Liposomal irinotecan + 5-FU 2 Toxicity-related discontinuation
*1/*28 Rectum IIA XELIRI 1 Toxicity-related hospitalization, death
UGT1A1: Irinotecan Normal Metabolizers





*1/*1 Colon IIIC FOLFIRI 8 No documented toxicity
*1/*1 Colon IVA XELIRI 7 No documented toxicity
*1/*1 Colon IIIB XELIRI 11 No documented toxicity
*1/*1 Pancreas III FOLFIRINOX 3 Toxicity-unrelated discontinuation
*1/*1 Pancreas IIB FOLFIRINOX 12 Toxicity-related dose reduction
DPYD: Intermediate Fluoropyrimidine Metabolizers 1
*c.557A>G/wt Stomach IB FOLFOX 1 Toxicity-related discontinuation
DPYD: Normal Fluoropyrimidine Metabolizers 2
wt Stomach III FOLFOX 10 No documented toxicity
wt Gastric IV XELOX 4 No documented toxicity
wt Gastric IIA FLOT 4 No documented toxicity





wt Colon IIIC XELOX 6 No documented toxicity
wt Rectum II XELOX 4 No documented toxicity
wt Colon IIIB FOLFOX 12 No documented toxicity
wt Rectum I Capecitabine + RT 45 d No documented toxicity
wt Colon IV FOLFOX + bevacizumab 10 No documented toxicity
wt Pancreas III Gemcitabine + capecitabine 8 No documented toxicity
wt Pancreas IIIB Gemcitabine + capecitabine 6 No documented toxicity
wt Colon IIIC FOLFIRI 8 No documented toxicity
wt Colon IVA XELIRI 7 No documented toxicity
wt Colon IIIB XELIRI 11 No documented toxicity
wt Rectum IV FOLFIRI 6 Toxicity-unrelated dose reduction





wt Pancreas IB Gemcitabine + capecitabine 1 Toxicity-unrelated discontinuation
wt Pancreas III FOLFIRINOX 3 Toxicity-unrelated discontinuation
wt Colon IIA FOLFOX 10 Toxicity-related dose reduction
wt Colon IIB FOLFOX 7 Toxicity-related dose reduction, cycle delay
wt Colon IIIB FOLFOX + bevacizumab 11 Toxicity-related dose reduction
wt Esophagus IVC FLOT 4 Toxicity-related dose reduction















Site Stage Regimen Cycles Notes
DPYD: Normal Fluoropyrimidine Metabolizers 2
wt Colon IIIA XELOX 4 Toxicity-related dose reduction





wt Colon III Capecitabine 1 Toxicity-related discontinuation
wt Colon IVA XELIRI 1 Toxicity-related discontinuation





Toxicity-related dose reduction, cycle delay
wt Colon IIIB FOLFOX + bevacizumab 5 Toxicity-related discontinuation,hospitalization
TPMT: Poor Mercaptopurine Metabolizer
*3B/*3C ALL N/A POMP 17 Toxicity-related dose reduction
CYP2D6: Intermediate Tamoxifen Metabolizer
*1/*6 Breast IV Tamoxifen 20 mg daily 8 mo Progressive disease; proceeded to surgicalcastration
Abbreviations: wt: wild type; FOLFOX: folinic acid, fluorouracil, and oxaliplatin; FLOT: fluorouracil, leucovorin, oxaliplatin, and docetaxel;
RT: radiation therapy; d: days; XELOX: capecitabine and oxaliplatin; 5-FU: 5-fluorouracil; FOLFIRI: folinic acid, fluorouracil, and irinotecan;
FOLFIRINOX: folinic acid, fluorouracil, irinotecan, and oxaliplatin; ALL: acute lymphoblastic leukemia; POMP: prednisone, vincristine,
methotrexate, 6-mercaptopurine; mg: milligrams; mo: months. 1 One pancreatic cancer patient whose genotype was DPYD*2A/wt was
treated with FOLFOX at an outside institution and follow-up data were not available for report. 2 Eight DPYD wild-type colorectal cancer
patients were treated with fluoropyrimidine-containing regimens at outside institutions and follow-up data were not available for report.
Appendix C
Table A3. Pharmacogenomically-relevant treatment regimens with associated dosing.
Regimen Dosing
FOLFIRI Irinotecan 180 mg/m
2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 2400 mg/m2 CI
every 14 d
FOLFIRINOX Irinotecan 180 mg/m
2, leucovorin 400 mg/m2, oxaliplatin 85 mg/m2, 5-FU 400 mg/m2 bolus,
then 2400 mg/m2 CI every 14 d
Liposomal irinotecan + 5-FU Liposomal irinotecan 70 mg/m2, leucovorin 400 mg/m2, 5-FU 2400 mg/m2 CI every 14 d
XELIRI Irinotecan 80–200 mg/m2 and capecitabine 800–1000 mg/m2 twice daily every 21 d
Irinotecan + cetuximab Irinotecan 180 mg/m2 and cetuximab 250–400 mg/m2 every 14 d
FOLFOX Leucovorin 400 mg/m
2, oxaliplatin 85 mg/m2, 5-FU 2400 mg/m2 CI +/− 400 mg/m2 bolus
every 14 d
XELOX Oxaliplatin 130 mg/m
2 and capecitabine 850–1000 mg/m2 twice daily every 21 d or
Oxaliplatin 85 mg/m2 and capecitabine 850–1000 mg/m2 twice daily every 14 d
FLOT Leucovorin 200 mg/m
2, docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, 5-FU 2600 mg/m2 CI every
14 d
Capecitabine + RT 825 mg/m2 twice daily during radiation treatments
Capecitabine 850 mg/m2 twice daily every 14–28 d
Gemcitabine + capecitabine Gemcitabine 1000 mg/m
2 weekly and capecitabine 650 mg/m2 twice daily every 21 d or
Gemcitabine 1000 mg/m2 weekly and capecitabine 830 mg/m2 twice daily every 14 d
Cisplatin + capecitabine Cisplatin 80 mg/m2 and capecitabine 1000 mg/m2 twice daily every 21 d
POMP Vincristine 1.4 mg/m
2, mercaptopurine 60 mg/m2, methotrexate 20 mg/m2, prednisone
30 mg/m2 every 28 d
Abbreviations: mg: milligrams; m2: meters squared; 5-FU: 5-fluorouracil; CI: continuous infusion; d: days; RT: radiation therapy.
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Appendix D
Table A4. List of CPIC level A pharmacogenes, associated anti-cancer drugs, and their indications.
Pharmacogene Drug Indication
CYP2D6 Tamoxifen Hormone-mediated cancers
DPYD Capecitabine
Fluorouracil
Chemotherapy; see Table 3
Chemotherapy; see Table 3
TPMT Mercaptopurine
Thioguanine
Leukemia, Chron disease/ulcerative colitis, other autoimmune disease
Leukemia
UGT1A1 Irinotecan Chemotherapy; see Table 3
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